According to a recent study, investigators uncovered key risk factors for disease recurrence in moderate-to-severe atopic dermatitis (AD) patients after dupilumab discontinuation.
Early onset of HS more prevalent in females
According to a recent study, findings from a new study examining pediatric hidradenitis suppurativa (HS) found patients experience a significant delay in diagnosis. Researchers also linked the predominance of HS in female children with earlier age of onset and age at diagnosis.
Lebrikizumab effective in treating head, neck AD
According to a recent study, lebrikizumab, a monoclonal antibody targeting IL-13, is effective in treating head and neck atopic dermatitis (AD) and erythema at 16 weeks of treatment.
Potential link between skin cancer and serum 25-hydroxyvitamin D levels
According to a recent study, skin cancer risk may be associated with higher levels of serum 25-hydroxyitamin D (serum 25(OH)D) levels.
Severe chronic hand eczema patients are more willing to make time for treatment
According to a recent study, patients with more severe chronic hand eczema were willing to dedicate a substantial amount of time daily for treatment.
Concomitant methotrexate adds no benefit to PsO treatment compared to adalimumab monotherapy
According to a recent study, treating psoriasis with adalimumab and concomitant methotrexate has no difference in effectiveness and persistence when compared to adalimumab monotherapy.
Patient QoL, disease burden for PsO may be similar whether high or low BSA
According to a recent study, psoriasis patients with low body surface area (BSA) involvement may experience similar quality of life (QoL) and disease burden as patients with high BSA.
Risk factors for anxiety, depression in AD patients identified
In a recent study, researchers have identified specific risk factors for anxiety and depression in atopic dermatitis (AD) patients, including a lower education level and severe pruritus.
Guselkumab effective in scalp PsO across all skin tones
According to a recent study, guselkumab is effective in treating moderate-to-severe scalp psoriasis in patients with Fitzpatrick Skin Types IV through VI.
GPP patients have five times higher mortality risk than those without
According to a recent study, patients with generalized pustular psoriasis (GPP) have a five times higher risk of all-cause mortality at one year than those without GPP.
HealthMinute.TV 